Merck paid $8.4 Billion for Cubist's Dapto and a pipeline of unapproved antibiotics. I remain disappointed and flummoxed that Leo didn't/couldn't find a partner for B-Absssi. I firmly believe this single disappointment, more than any other issue depresses the SP to this day and will until a credible partner is signed to a material deal which I assume will be B-OM this Q. I anticipate that a B-OM partnership will increase interest in the entire B franchise, including Absssi.